SGLT-2 inibitori nel trattamento dell’iponatremia. Quale ruolo?
Authors:
Open Access
- 28 February 2024
- journal article
- rassegna
- Published by Springer Nature in L'Endocrinologo
- Vol. 25 (2) , 145-150
Abstract
Sommario: Gli inibitori del cotrasportatore Na+-glucosio di tipo 2 inducono glicosuria e diuresi osmotica. L’aumento dell’escrezione di acqua libera, che riduce il volume circolante e determina cardio- e nefroprotezione indipendenti dall’azione ipoglicemizzante, li rende potenzialmente efficaci nei pazienti con iponatremia cronica, un disturbo elettrolitico gravato da elevate morbilità e mortalità per il quale le opzioni terapeutiche a disposizione sono poche e spesso poco tollerate, inefficaci o costose.Keywords
Funding Information
- Università degli Studi di Firenze
This publication has 19 references indexed in Scilit:
- Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: a case report and literature reviewHormones, 2023
- Relationship of Dapagliflozin With Serum SodiumJACC: Heart Failure, 2022
- Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failureEuropean Journal of Heart Failure, 2020
- Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney functionKidney International, 2020
- Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic RatsThe American Journal of the Medical Sciences, 2016
- Predictors of nonresponse to fluid restriction in hyponatraemia due to the syndrome of inappropriate antidiuresisJournal of Internal Medicine, 2016
- Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresisKidney International, 2016
- Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel RecommendationsThe American Journal of Medicine, 2013
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes MellitusClinical Pharmacology & Therapeutics, 2009